BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26933086)

  • 21. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
    Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
    Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
    Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
    Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
    BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
    Deng X; Li Q; Hoff J; Novak M; Yang H; Jin H; Erfani SF; Sharma C; Zhou P; Rabinovitz I; Sonnenberg A; Yi Y; Zhou P; Stipp CS; Kaetzel DM; Hemler ME; Yang XH
    Neoplasia; 2012 Aug; 14(8):678-89. PubMed ID: 22952421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
    Bui T; Schade B; Cardiff RD; Aina OH; Sanguin-Gendreau V; Muller WJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E707-E716. PubMed ID: 28096336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.
    Yu M; Lin G; Arshadi N; Kalatskaya I; Xue B; Haider S; Nguyen F; Boutros PC; Elson A; Muthuswamy LB; Tonks NK; Muthuswamy SK
    Mol Cell Biol; 2012 Oct; 32(19):3913-24. PubMed ID: 22851698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
    Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
    Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
    Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
    Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.
    Campbell CI; Petrik JJ; Moorehead RA
    Mol Cancer; 2010 Sep; 9():235. PubMed ID: 20825649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.
    Shen Q; Uray IP; Li Y; Zhang Y; Hill J; Xu XC; Young MR; Gunther EJ; Hilsenbeck SG; Colburn NH; Chodosh LA; Brown PH
    Cancer Prev Res (Phila); 2008 Jun; 1(1):45-55. PubMed ID: 19138935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.
    Zhang Q; Sakamoto K; Liu C; Triplett AA; Lin WC; Rui H; Wagner KU
    Cancer Res; 2011 Dec; 71(24):7513-24. PubMed ID: 22037875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Environmental cadmium exposure facilitates mammary tumorigenesis via reprogramming gut microbiota-mediated glutamine metabolism in MMTV-Erbb2 mice.
    Yue Y; Zhang H; Deng P; Tan M; Chen C; Tang B; Li J; Chen F; Zhao Q; Li L; Hao R; Wang H; Luo Y; Tian L; Xie J; Chen M; Yu Z; Zhou Z; Pi H
    Sci Total Environ; 2023 Nov; 897():165348. PubMed ID: 37429473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
    Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
    Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.